• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results; Does Clinical Breast Examination Lead to Earlier Breast Cancer Diagnoses in Low- and Middle-Income Countries?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • In low- and middle-income countries, breast cancer is often detected at advanced stages
  • Clinical breast examination (CBE) may be a good screening method in this setting
  • Mittra et al. (BMJ, 2021) examined the efficacy of screening by CBE in downstaging breast cancer at diagnosis and in reducing mortality

METHODS:

  • Prospective, cluster randomized controlled trial
  • Setting
    • 20 geographically distinct clusters located in Mumbai, India over 20 years (May 1998 to March 2019)
      • 10 clusters were designated as screening clusters, and 10 as controls
  • Participants
    • Women aged 35 to 64
    • No history of breast cancer
  • Interventions
    • Screening
      • 4 screening rounds of clinical breast examination (conducted by trained female primary health workers) and cancer awareness every two years
      • Followed by five rounds of active surveillance every two years
    • Control
      • One round of cancer awareness
      • Followed by eight rounds of active surveillance every two years
  • Health workers who performed CBE
    • Passed 10th grade education
    • Training period of approximately 4 weeks
  • Primary outcomes
    • Downstaging of breast cancer at diagnosis
    • Reduction in mortality from breast cancer

RESULTS:

  • Screening arm: 75,360 women | Control arm: 76,178 women
  • Breast cancer was detected at an earlier age in the screening group (P = 0.01)
    • Screening: mean age 55.18 years
    • Control: 56.50 years
  • There was a significant reduction in the proportion of women with stage III or IV disease in the screening group (P = 0.001)
    • Screening: 37%
    • Control: 47%
  • 15% reduction in breast cancer mortality was observed in the screening arm but was non-significant (P = 0.07)
    • Screening: 20.82 deaths/100,000 person years (95% CI, 18.25 to 23.97)
    • Control: 24.62 (95% CI, 21.71 to 28.04)
    • Rate ratio 0.85 (95% CI, 0.71 to 1.01)
  • There was a reduction in breast cancer mortality in women aged ≥50 on post-hoc analysis (P = 0.02)
    • Screening: 24.62 deaths/100,000 person years (95% CI, 20.62 to 29.76)
    • Control: 34.68 (95% CI, 27.54 to 44.37)
    • Rate ratio 0.71 (95% CI, 0.54 to 0.94)
  • There was no significant reduction in women <50 (P = 0.37)
  • There was no difference in all cause mortality between groups (P = 0.49)
    • Rate ratio 0.95 (95% CI, 0.81 to 1.10)
    • Authors note that “because breast cancer deaths comprise less than 3% of all deaths in women in India, we did not expect a reduction in all cause mortality in our study”

CONCLUSION:

  • Clinical breast examination led to a significant downstaging of breast cancer at diagnosis
  • While a 15% reduction in overall breast cancer mortality was not significant, there was a significant 30% reduction in women over 50 years of age
  • The authors conclude that clinical breast examination is a viable screening option for low- and middle-income countries

Learn More – Primary Sources:

Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai

Now You Can Get Mobile-Friendly ObG Clinical Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

High-Deductible Health Care Plans and Delayed Breast Cancer Treatment
How Do Health Outcomes in the Richest Counties in the US Compare to Those of Average Citizens in Other Developed Nations?
How Effective Is Mammography in Reducing the Number of Advanced Breast Cancer Diagnoses?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site